Literature DB >> 18035071

Rationale and design of a prospective study of the efficacy of a remote monitoring system used in implantable cardioverter defibrillator follow-up: the Lumos-T Reduces Routine Office Device Follow-Up Study (TRUST) study.

Niraj Varma1.   

Abstract

Increased implantable cardioverter defibrillator (ICD) implant volumes (and product advisories/recalls) pose management challenges. Most device interrogations at 3- to 6-month routine follow-up visits are "nonactionable," that is, require no clinically significant reprogramming, lead revision, or initiation or up-titration of antiarrhythmic medications. Conversely, implanted devices collect important diagnostic data (eg, atrial fibrillation onset, system integrity) that remain concealed between device interrogations. Remote monitoring may resolve some of these challenges, but has not been studied in a large-scale clinical trial. Home Monitoring (HM) uses automatic (without patient intervention) data and electrogram transmissions with rapid (<24 hours) event notification of significant (including silent) events. The Lumos-T Reduces Routine Office Device Follow-Up Study (TRUST) is a multicenter, prospective, randomized study enrolling 1000 ICD patients designed to test whether HM can safely reduce the number of scheduled nonactionable office device interrogations by 50% and provide early detection and notification of cardiac and/or device problems. After enrollment, TRUST patients are randomized 2:1 to either HM or to control (ie, HM off) arms and are seen for an in-office follow-up 3 months postimplant. At subsequent 3-month intervals, control patients have conventional office visits, whereas in HM, patient data are remotely retrieved and evaluated. In HM patients, early notification may automatically occur between periodic checks for compromised system integrity (battery, lead parameters, high-voltage circuitry) or arrhythmia occurrence (eg, atrial fibrillation, ventricular arrhythmia). All study patients will have a final office visit 15 months after implant. The results of TRUST may confirm the role of remote monitoring as an intensive surveillance mechanism for device management.

Entities:  

Mesh:

Year:  2007        PMID: 18035071     DOI: 10.1016/j.ahj.2007.07.051

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  10 in total

Review 1.  Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity.

Authors:  Oussama Wazni; Bruce L Wilkoff
Journal:  Nat Rev Cardiol       Date:  2010-04-20       Impact factor: 32.419

Review 2.  Advances in remote monitoring of implantable pacemakers, cardioverter defibrillators and cardiac resynchronization therapy systems.

Authors:  Werner Jung; Andreas Rillig; Ralf Birkemeyer; Tomislav Miljak; Udo Meyerfeldt
Journal:  J Interv Card Electrophysiol       Date:  2008-09-27       Impact factor: 1.900

3.  Remote monitoring of implanted cardiac devices: a plea for a nationwide exploration.

Authors:  N M van Hemel
Journal:  Neth Heart J       Date:  2009-11       Impact factor: 2.380

4.  Therapeutic implications of automatic home monitoring of implantable cardiac devices.

Authors:  Niraj Varma
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-10

5.  [Telemedicine in pacemaker therapy and follow-up].

Authors:  A Schuchert
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2009-12

Review 6.  Remote monitoring of patients with implanted cardiac devices.

Authors:  Fred Kusumoto; Nora Goldschlager
Journal:  Clin Cardiol       Date:  2010-01       Impact factor: 2.882

7.  Same-day discovery of implantable cardioverter defibrillator dysfunction in the TRUST remote monitoring trial: influence of contrasting messaging systems.

Authors:  Niraj Varma; Behzad B Pavri; Bruce Stambler; Justin Michalski
Journal:  Europace       Date:  2012-12-19       Impact factor: 5.214

Review 8.  Remote monitoring and follow-up of pacemakers and implantable cardioverter defibrillators.

Authors:  Haran Burri; David Senouf
Journal:  Europace       Date:  2009-06       Impact factor: 5.214

Review 9.  Telemedicine and cardiac implants: what is the benefit?

Authors:  Niraj Varma; Renato Pietro Ricci
Journal:  Eur Heart J       Date:  2012-12-04       Impact factor: 29.983

10.  Superiority of automatic remote monitoring compared with in-person evaluation for scheduled ICD follow-up in the TRUST trial - testing execution of the recommendations.

Authors:  Niraj Varma; Justin Michalski; Bruce Stambler; Behzad B Pavri
Journal:  Eur Heart J       Date:  2014-03-03       Impact factor: 29.983

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.